-
Pfizer: JAK1 inhibitor Xibico has been approved as a new indication for age expansion in China
Pfizer: JAK1 inhibitor Xibico has been approved as a new indication for age extension in China. Pfizer announced that the highly selective JAK1 inhibitor and innovative oral small molecule targeted d ... -
The first PD-L1 inhibitor for the treatment of gastric cancer, Pfizer Zeteme, has been approved for its fifth indication
On March 15th, Pfizer announced that its innovative tumor immunotherapy drug, Serenigme (Shuglizumab Injection), has been approved by the National Medical Products Administration for first-line treat ... -
Baishime Squibb: Myosin inhibitor Maifantuo? Approved in China for the treatment of adult patients with obstructive hypertrophic cardiomyopathy
On April 30th, Bristol Myers Squibb announced that it was the world's first myocardial myosin inhibitor, Mefantuo& Reg; (Common name: Mavakaitai Capsules) has been given priority review and approval ...